Track Halozyme Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Halozyme Therapeutics, Inc. HALO · Stock Open Halozyme Therapeutics, Inc. in new tab

100.27 USD
P/E
25.07
EPS
4.00
P/B
-206.74
ROE
216.38
Beta
0.90
Target Price
119.89 USD
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc.

🧾 Earnings Recap – Q2 2026

Halozyme shares surged 23.4% as the company delivered robust royalty revenue growth driven by strong ENHANZE platform adoption, record new collaboration agreements, and an increased full-year 2026 guidance.

  • Total revenue rose 48% year-over-year to $481 million, led by royalty revenue growth of 50% to $308 million.
  • New collaboration and licensing agreements hit a record pace with five new deals (three for ENHANZE, two for Hypercon), generating $35.5 million in upfront revenue.
  • Raised full-year 2026 revenue guidance by $112.5 million at the midpoint, reflecting strength from established and new subcutaneous product launches.
  • ENHANZE-enabled subcutaneous products OCREVUS ZUNOVO, OPDIVO Qvantig, and RYBREVANT SC contributed significantly, with patient starts and conversion rates growing rapidly.
  • Adjusted EBITDA reached $329 million with a margin exceeding 65%, demonstrating operational leverage from the diversified royalty portfolio.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 16, 2027
P/E25.07
EPS4.00
Book Value-0.49
Price to Book-206.74
Debt/Equity1517.69
% Insiders2.454%
Growth
Revenue Growth0.39%
Earnings Growth0.41%
Estimates
Forward P/E9.47
Forward EPS10.59
Target Mean Price119.89

DCF valuation

Model fair value for Halozyme Therapeutics, Inc. (HALO)
Result
Sign in to run the valuation for HALO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Buy · mean target 119.89 USD (low 79.00, high 149.00) · as of 16 Nov 2026
Low 79.00
Mean 119.89
High 149.00
Price 100.27
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Halozyme Therapeutics, Inc. Logo Halozyme Therapeutics, Inc. Analysis (HALO)

United States Health Care Official Website Stock

Is Halozyme Therapeutics, Inc. a good investment? Halozyme Therapeutics, Inc. (HALO) is currently trading at 100.27 USD. Market analysts have a consensus price target of 119.89 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 25.07. This valuation is generally in line with the broader market.

Earnings Schedule: Halozyme Therapeutics, Inc. is expected to release its next earnings report on Feb. 16, 2027. The market consensus estimate for Forward EPS is 10.59.

Investor FAQ

Does Halozyme Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Halozyme Therapeutics, Inc.?

Halozyme Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 16, 2027. The company currently has a trailing EPS of 4.00.

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Exchange Ticker
FRA (Germany) RV7.F
LSE (United Kingdom) 0J2O.L
NMS (United States) HALO
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion